Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12809459 | 0.94 | CTSK (0.44) | CTSK | |
| SCHEMBL10266406 | 0.89 | CTSK (0.40) | CTSK | |
| SCHEMBL1401076 | 0.86 | CTSK (0.41) | CTSK | |
| SCHEMBL1401074 | 0.86 | CTSK (0.41) | CTSK | |
| SCHEMBL29679376 | 0.84 | CTSK (0.54) | CTSK | |
| SCHEMBL11929410 | 0.84 | CTSK (0.51) | CTSK | |
| SCHEMBL5493959 | 0.76 | CTSK (0.59) | CTSK | |
| SCHEMBL5493965 | 0.76 | CTSK (0.59) | CTSK | |
| SCHEMBL2771197 | 0.74 | CTSK (0.56) | CTSK | |
| SCHEMBL10266633 | 0.73 | CTSK (0.45) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | PTGER4, PTGER1, PTGER2 | CTSK 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.